联邦制药品牌怎么样 申请店铺

联邦制药1990年成立于香港。1994年，投资数亿港元创建珠海联邦制药股份有限公司，以先进的制药技术，科学的管理，卓越的服务，怀着为中国人民健康服务的热忱，提供多元化的产品，特别是抗菌素产品，以及该种产品的原料药和中间体，全力促进中国医药健康事业的发展。

联邦制药拥有6家生产基地，包括香港联邦制药厂有限公司（制剂）、珠海联邦制药股份有限公司（原料）、珠海联邦制药股份有限公司中山分公司（制剂）、联邦制药金亿胶囊厂（空心胶囊）、联邦制药（内蒙古）有限公司（中间体）、金桂制药有限公司（兽药）。联邦制药集药品研发、生产、经营为一体，从生物发酵开始集医药中间体、原料药、药物制剂、药包材生产为一体，实现垂直一体化的生产经营模式，以优质的售后服务网络、完善的市场信息反馈系统、严谨的质量保证体系，为联邦制药卓越的产品质量奠定了坚实的基础。2007年6月15日，联邦制药国际控股有限公司在香港成功上市，标志着联邦制药步上了一个新的发展平台，为立足香港，辐射全球，实现企业品牌的快速扩张拓展了广阔的空间。

联邦制药拥有世界一流的生产设备。年生产能力为胶囊剂15.4亿粒，片剂10.8亿片，颗粒剂1.15亿袋，混悬剂2000万袋，口服液2000万瓶，粉针剂1.3亿瓶，软膏剂4500万支，冻干粉针1950万瓶，滴眼剂2400万支，胰岛素2400万瓶，年生产能力一举跃上新台阶。联邦制药在多个产品一路领先，国家火炬计划重点高新技术企业、广东省高新技术企业、中国制药专业博士后科研工作站、中国制药工业百强、广东省先进集体，每一个享誉业界的称号，充分证明了联邦制药的综合实力；国内首批全厂所有剂型一次性通过国家GMP认证的制药企业，160多种药物的研发，上百种医药批件的取得，每一个富有价值的金字招牌，都充分体现了联邦制药的领先水平。

联邦制药一如既往地秉承“让生命更有价值”的承诺，致力推动中国医药卫生事业的发展，为社会提供更多优质高效的医药产品。

UL was founded in Hong Kong in 1990. In 1994, the company invested hundreds of millions of Hong Kong dollars to establish Zhuhai federal Pharmaceutical Co., Ltd. with advanced pharmaceutical technology, scientific management, excellent service, with the enthusiasm of serving the Chinese people's health, to provide a wide range of products, especially antibiotic products, as well as raw materials and intermediates of this product, to promote the development of China's pharmaceutical health industry. UL has 6 production bases, including Hong Kong federal Pharmaceutical Co., Ltd. (preparations), Zhuhai federal Pharmaceutical Co., Ltd. (raw materials), Zhongshan branch of Zhuhai federal Pharmaceutical Co., Ltd. (preparations), UL Jinyi Capsule Factory (hollow capsules), UL Inner Mongolia Co., Ltd. (intermediates), Jin Gui pharmaceutical Co., Ltd. (veterinary drugs) 。 With the integration of drug research and development, production and operation, and the integration of pharmaceutical intermediates, APIs, pharmaceutical preparations and drug packaging materials from the start of biological fermentation, UL has realized the vertically integrated production and operation mode. With its high-quality after-sales service network, perfect market information feedback system and strict quality assurance system, UL has laid a solid foundation for its excellent product quality Foundation. On June 15, 2007, UL International Holdings Co., Ltd. successfully listed in Hong Kong, marking that UL has stepped onto a new development platform, expanding broad space for its foothold in Hong Kong, global radiation and rapid expansion of corporate brands. UL has world-class production facilities. The annual production capacity is 1.54 billion capsules, 1.08 billion tablets, 115 million bags of granules, 20 million bags of suspension, 20 million bottles of oral liquid, 130 million bottles of powder injection, 45 million bottles of ointment, 19.5 million bottles of lyophilized powder injection, 24 million bottles of eye drops and 24 million bottles of insulin. The annual production capacity has leaped to a new level. UL is leading the way in a number of products, including key high-tech enterprises under the national Torch Program, high-tech enterprises in Guangdong Province, postdoctoral research stations of Chinese pharmaceutical specialty, top 100 pharmaceutical enterprises in China, and advanced collective in Guangdong Province, each of which is known as the title of the industry, fully proving the comprehensive strength of UL. All the dosage forms of the first batch of the whole factory in China have passed the national GMP certification once and for all The pharmaceutical enterprises with certificates, the R & D of more than 160 kinds of drugs, the acquisition of hundreds of medical approvals, and each valuable gold brand fully reflect the leading level of UL. As always, UL adheres to the commitment of "making life more valuable", and is committed to promoting the development of China's medical and health undertakings, so as to provide more high-quality and efficient medical products for the society.

本文链接： https://brand.waitui.com/5d34d6cac.html